Therapy resistance, not only in hematological malignancies but across various tumor types, has increasingly been attributed in part to the overexpression of anti-apoptotic Bcl-2 protein family members, particularly BCL-xL and MCL-1 [45, 46]. Here, BCL2 is linked to neoplasm.